Özkan Alan
YOU?
Author Swipe
View article: Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study Open
Background: Durvalumab combined with gemcitabine–cisplatin (GC) has become the standard first-line treatment for advanced biliary tract cancer (BTC) following the TOPAZ-1 trial. However, real-world effectiveness, safety, and prognostic det…
View article: Inflammatory and Nutritional Markers Predicting Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Multicenter Real-World Study
Inflammatory and Nutritional Markers Predicting Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Multicenter Real-World Study Open
Background: Pathological complete response (pCR) following neoadjuvant therapy (NAT) is a key surrogate marker for long-term outcomes in HER2-positive breast cancer. Identifying clinical and biological predictors of pCR, including systemic…
View article: #3494 Incidence and frequency of immune-related nephropathy in patients treated with immune checkpoint inhibitors: a FAERS analysis (2020–2024)
#3494 Incidence and frequency of immune-related nephropathy in patients treated with immune checkpoint inhibitors: a FAERS analysis (2020–2024) Open
Background and Aims Immune checkpoint inhibitors (ICIs) are widely used in cancer immunotherapy, but their use is associated with immune-related adverse events, including immune-related nephropathy. This study aims to evaluate the incidenc…
View article: Evaluating the Prognostic Role of Pan-Immune-Inflammation Value in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
Evaluating the Prognostic Role of Pan-Immune-Inflammation Value in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab Open
Objective: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related death. Panimmune-inflammation value (PIV), a novel biomarker that reflects systemic inflammation and immune status, has been evaluated for prognostic e…
View article: Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases
Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases Open
Background: This retrospective study compared the effectiveness and preliminary cost evaluation of denosumab and zoledronic acid (ZA) in patients with bone metastases from breast, prostate, and lung cancer. Methods: Patients treated with Z…
View article: Is Body Mass Index a Prognostic Factor in Metastatic HER2-Positive Breast Cancer? A Real-World Multicenter Study
Is Body Mass Index a Prognostic Factor in Metastatic HER2-Positive Breast Cancer? A Real-World Multicenter Study Open
Background and Objectives: The prognostic significance of body mass index (BMI) in metastatic HER2-positive breast cancer (BC) remains unclear, with previous studies yielding conflicting results. This multicenter real-world study aimed to …
View article: Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer
Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer Open
Background and Objectives: Breast cancer is a leading cause of cancer-related mortality, particularly in aggressive subtypes such as HER2-positive and triple-negative breast cancer (TNBC). Achieving a pathological complete response (pCR) a…
View article: Immune-Mediated Upper Gastrointestinal System Toxicities in Patients Receiving Immune Checkpoint Inhibitors: An Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS)
Immune-Mediated Upper Gastrointestinal System Toxicities in Patients Receiving Immune Checkpoint Inhibitors: An Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Open
Background: Immune-mediated (im) upper gastrointestinal (GI) toxicities refer to inflammatory damage of oesophagus, stomach and duodenum following immune checkpoint inhibitors (ICIs) use. Given its rarity and vague symptoms, diagnosis is o…
View article: First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data
First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data Open
Background: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer frequently involves liver metastases, which are linked to poor outcomes. The optimal first-line treatment strateg…
View article: Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations Open
Background and Objectives: Despite advances in immunotherapy, predicting survival outcomes in patients with non-small-cell lung cancer (NSCLC) remains challenging. Inflammatory and nutritional indices such as the Prognostic Nutritional Ind…
View article: The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis Open
Our research demonstrates that the addition of carboplatin increases pCR rates in both HER2-zero and HER2-low patient cohorts. We suggest that carboplatin should be considered as an addition to standard neoadjuvant chemotherapy for eligibl…
View article: Prognostic Significance of Inflammatory and Nutritional Biomarkers in Patients with Metastatic Gastric Cancer
Prognostic Significance of Inflammatory and Nutritional Biomarkers in Patients with Metastatic Gastric Cancer Open
Objective: Metastatic gastric cancer (mGC) is an incurable disease and a leading cause of cancer-related deaths worldwide. The prognostic significance of systemic inflammation and nutritional scores in patients with mGC has been investigat…
View article: Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach
Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach Open
Immune checkpoint inhibitors (ICIs) have transformed the field of cancer immunotherapy and led to substantial improvements in patient outcomes across various malignancies. Neurological toxicities arising from ICI treatment represent a hete…
View article: Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)
Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG) Open
Background/Aims: The treatment of hepatocellular carcinoma (HCC), which accounts for 90% of all liver cancers, is highly varied. The use of second-line treatments following progression on first-line atezolizumab and bevacizumab (Atez/Bev) …
View article: The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors
The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors Open
Background/Objectives: CDK4/6 inhibitors have changed the landscape of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (BC) management. It is essential to identify predictiv…
View article: Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors
Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors Open
Introduction: CDK 4/6 inhibitors are effectively utilized among patients with hormone-positive, HER-2-negative metastatic breast cancer. The dose reduction for these patients varies between 35% and 57% across multiple trials. We aim to cla…
View article: Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients
Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients Open
Background and Objectives: Obesity is a significant risk factor for the development of breast cancer (BC) and associated poorer outcomes. A pathological complete response (pCR) with neoadjuvant chemotherapy (NACT) correlates with improved …
View article: Denosumab administration in breast, prostate and lung cancer with chronic kidney disease – a retrospective multicenter Turkish Oncology Group (TOG) study
Denosumab administration in breast, prostate and lung cancer with chronic kidney disease – a retrospective multicenter Turkish Oncology Group (TOG) study Open
Background Denosumab, a RANK-ligand inhibitor, is an effectivetreatmentforfor bone metastasesfromsolidtumors.Unlikethebisphosphonates, it is not excretedbythekidney. Little is known, however, aboutitsefficacyandsafety in patientswith sever…
View article: Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older
Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older Open
Background: Lung cancer remains the leading cause of cancer-related mortality globally, predominantly affecting older individuals. Despite the increasing use of immune checkpoint inhibitors (ICIs) like nivolumab in non-small cell lung canc…
View article: Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy
Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy Open
Background: We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC). Methods: This is a retrospective de…
View article: Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older
Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older Open
Background: Lung cancer remains the leading cause of cancer-related mortality globally, predo-minantly affecting older individuals. Despite the increasing use of immune checkpoint inhibitors (ICIs) like nivolumab in non-small cell lung can…
View article: Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT
Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT Open
This study represents the first comprehensive investigation of plasma ccfDNA levels, mtDNAcn, and integrities collectively. Furthermore, it is the first study to explore the relationship between these markers and CTCs, cancer stem cell mar…
View article: Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis
Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis Open
Background and Objectives: Lung cancer is the leading cause of cancer-related deaths. Spread through air spaces (STAS) is an adverse prognostic factor that has become increasingly known in recent years. This study aims to investigate the i…
View article: A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐<scp>5FU</scp> and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study
A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐<span>5FU</span> and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study Open
Background Neoadjuvant treatment is the standard treatment in locally advanced ESCC. However, the optimal chemotherapy regimen is not known. Method This is a retrospective observational cohort study conducted with propensity score matching…
View article: Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG) Open
Objectives Head and neck cancers (HNCs) represent a significant global health concern due to high morbidity and mortality rates. Despite therapeutic advances, the prognosis for advanced or recurrent cases remains challenging. Nivolumab obt…